A1C reduction
-
Efsitora Alfa (Lilly’s Once-Weekly Insulin) Shows A1C Reduction and Safety Profile Comparable to Daily Insulin in Phase 3 Trials
Lilly announced positive Phase 3 trial results for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated non-inferior A1C reduction compared to daily basal insulin. The company plans to submit efsitora for regulatory review by the end of the year.
-
Orforglipron: Lilly’s Oral GLP-1 Shows Strong Efficacy and Safety in Phase 3 Data Published in NEJM
Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.
